Improving Primary Care Management of IBS-D through Early Diagnosis and Personalized Treatment
September 17, 2018
September 17, 2019
Scroll to the Bottom of this Information to Begin this Course
Provided by Integrity Continuing Education.
This activity is supported by an independent education grant from Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC.
- Physicians — maximum of 1 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This educational initiative has been designed for primary care providers (PCPs), nurse practitioners, and physician assistants involved in the care of patients with IBS-D.
This case-based enduring activity will cover the diagnosis, treatment and management of patients with IBS-D.
Upon completion of this activity, participants should be able to:
- Apply an approach to the diagnosis of IBS-D that is consistent with current evidence-based guidelines
- Identify strategies for encouraging effective provider-patient communication to improve assessment of disease burden in patients with IBS-D
- Summarize current evidence regarding efficacy and safety of available options for the treatment of IBS-D
Lucinda Harris, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Gastroenterology & Hepatology
Mayo Clinic College of Medicine
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring material.
Disclosures of Conflicts of Interest
Lucinda Harris, MD, MS
- Consultant: Allergan, Napo Pharmaceuticals, Shire, Synergy
- Speakers’ Bureaus: Allergan, Ironwood
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of September 17, 2018 through September 17, 2019, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Course Viewing Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.